deal, page-4

Looking at the BOS ASX announcement,,,it looks like

1. BOS IP sold, maybe some is retained "license back"
2. Receive USD$2.6M in CBTE shares at $1.00, market value currently $0.78 per share therefore ~$2.028M USD less any liquidity discount, plus any future upside in stock price on closure of the GL biotechem deal.

Short answer - BOS raises ~$2M US in capital

3. Additional consideration by way of a Con note by BOS for UP TO 114M shares - This looks like a sort of performance based arrangement on the future of the BOS IP. Reading into it,,if the BOS IP does well, perhaps the sumber of shares to be issued is less than 114M. Either way, the issue of BOS shares at 0.03 seems like a good result

Short answer - Performance based returns on BOS IP with no downside risk of having to pay for it in CASH

4. No real news on the major aquisition as yet - -keeps us guessing but with ~$2M in shares that can be traded it bodes well for a good deal to come with some value to be retained for the long suffering BOS holders.